Benitec Biopharma Inc. (BNTC)
NASDAQ (CM) NASDAQ (CM) Primary 
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)
Benitec Biopharma (BNTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others
In the past week or so, beneficial owners Carl Icahn and Mario Gabelli made some big bets in Monro Inc.
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Benitec Biopharma (BNTC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 66% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 83.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?
Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?
Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.
Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade
The consensus price target hints at an 85% upside potential for Benitec Biopharma (BNTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Benitec Biopharma (BNTC) a New Buy Stock
Benitec Biopharma (BNTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
